Vericel Corp (VCEL)
48.04
-0.61
(-1.25%)
USD |
NASDAQ |
May 10, 16:00
48.04
0.00 (0.00%)
After-Hours: 19:56
Vericel Research and Development Expense (Quarterly): 6.418M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.418M |
| December 31, 2023 | 4.901M |
| September 30, 2023 | 5.676M |
| June 30, 2023 | 5.253M |
| March 31, 2023 | 5.212M |
| December 31, 2022 | 5.245M |
| September 30, 2022 | 5.046M |
| June 30, 2022 | 4.792M |
| March 31, 2022 | 4.86M |
| December 31, 2021 | 3.924M |
| September 30, 2021 | 4.284M |
| June 30, 2021 | 4.449M |
| March 31, 2021 | 3.63M |
| December 31, 2020 | 3.118M |
| September 30, 2020 | 2.913M |
| June 30, 2020 | 3.226M |
| March 31, 2020 | 3.763M |
| December 31, 2019 | 3.217M |
| September 30, 2019 | 3.096M |
| June 30, 2019 | 21.07M |
| March 31, 2019 | 3.008M |
| December 31, 2018 | 3.018M |
| September 30, 2018 | 3.113M |
| June 30, 2018 | 3.739M |
| March 31, 2018 | 3.729M |
| Date | Value |
|---|---|
| December 31, 2017 | 3.587M |
| September 30, 2017 | 2.919M |
| June 30, 2017 | 2.971M |
| March 31, 2017 | 3.467M |
| December 31, 2016 | 4.258M |
| September 30, 2016 | 3.443M |
| June 30, 2016 | 4.058M |
| March 31, 2016 | 3.536M |
| December 31, 2015 | 7.404M |
| September 30, 2015 | 3.74M |
| June 30, 2015 | 3.369M |
| March 31, 2015 | 4.377M |
| December 31, 2014 | 5.793M |
| September 30, 2014 | 7.835M |
| June 30, 2014 | 4.364M |
| March 31, 2014 | 3.271M |
| December 31, 2013 | 3.315M |
| September 30, 2013 | 2.575M |
| June 30, 2013 | 3.676M |
| March 31, 2013 | 5.538M |
| December 31, 2012 | 6.013M |
| September 30, 2012 | 6.147M |
| June 30, 2012 | 7.069M |
| March 31, 2012 | 6.796M |
| December 31, 2011 | 5.904M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.913M
Minimum
Sep 2020
21.07M
Maximum
Jun 2019
5.205M
Average
4.620M
Median
Research and Development Expense (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | 9.867M |
| Arbutus Biopharma Corp | 15.40M |
| Chimerix Inc | 18.84M |
| Karyopharm Therapeutics Inc | 39.38M |
| Y-mAbs Therapeutics Inc | 13.39M |